CTTH (CTT Pharmaceutical Holdings) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CTT Pharmaceutical Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

CTT Pharmaceutical Holdings Valuation Rank Related Terms

CTT Pharmaceutical Holdings Business Description

Address 3853 Northdale Boulevard, Suite 268, Tampa, FL, USA, 33624
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.